Drugs / LY3857210
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05292040 | Mar → Dec 2022 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 24 trials · 3 missed | ||||||
| Phase 2 | NCT05630196 | Dec 2022 → Jun 2023 | chronic pain syndrome | Eli Lilly and Company | Completed | Missed primary |
| Phase 2 | NCT05620563 | Nov 2022 → Jun 2023 | osteoarthritis | Eli Lilly and Company | Completed | Missed primary |
| Phase 2 | NCT05620576 | Nov 2022 → Jul 2023 | diabetic polyneuropathy | Eli Lilly and Company | Completed | Missed primary |
| Phase 2 | NCT05986292 | Jan 2020 → Apr 2027 expected | chronic pain syndrome, diabetic neuropathy, osteoarthritis, knee | Eli Lilly and Company | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3857210 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05620563 ↗ |
| Route | Oral | “Administered orally.” NCT05292040 ↗ |